Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167586 | 0.83 | MAP2K2 (0.44) | IKBKBKMT2AKDM4EMAP2K2MAP2K1 | |
| SCHEMBL27682200 | 0.83 | KDM4E (0.63) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL29622706 | 0.83 | KDM4E (0.63) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL145394 | 0.83 | KDM4E (0.63) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL2327264 | 0.81 | KDM4E (0.41) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| Ammonia Solution, Strong SCHEMBL2316519 | 0.81 | KDM4E (0.61) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL31373249 | 0.80 | MAP2K2 (0.41) | IKBKBKMT2AKDM4EMAP2K2MAP2K1 | |
| SCHEMBL1708814 | 0.77 | KMT2A (0.65) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL9578379 | 0.77 | IKBKB (0.81) | IKBKBKMT2AKDM4EGFERRXFP1 | |
| SCHEMBL1477485 | 0.77 | MAP2K1 (0.54) | MAP2K2MAP2K1PTPRCPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213506-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-115943144-B | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-112566906-B | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2024-11-12 | — | — | CN | disclosed |
| US-12053443-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118359548-A | Preparation method of benzodiazepine compound | 重庆医科大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| CN-113209066-B | Amino-aryl-benzamide compounds and methods of use thereof | 上海赫普化医药技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4234536-A2 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Hepanova, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-115943144-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
| CN-1052002-C | Ether derivatives of tetrahydropyran and tetrahydrofuran, process for their preparation and pharmaceutical compositions containing them | ZENECA LTD (GB) | 2000-05-03 | — | — | CN | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| CN-1121715-A | 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| US-5512594-A | ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | IKBKB 2437/4885KMT2A 1161/4885KDM4E 1818/4885 |
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | IKBKB 878/4885KMT2A 2643/4885KDM4E 2065/4885 |
| US-20250213506-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | IKBKB 1103/4885KMT2A 771/4885KDM4E 787/4885 |
| US-12053443-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | IKBKB 1103/4885KMT2A 771/4885KDM4E 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.